# Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

> **NCT00614523** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 250 (actual)

## Conditions studied

- MDS
- Myelodysplastic Syndromes
- Thrombocytopenia

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** Romiplostim

## Key facts

- **NCT ID:** NCT00614523
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-21
- **Primary completion:** 2011-03-31
- **Final completion:** 2015-11-30
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614523, "Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00614523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*